Waters Corporation (WAT) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Waters Corporation (NYSE:WAT) CEO Udit Batra, speaking at the Wells Fargo Healthcare Conference, reported consistent strength in the company's base business, achieving another quarter of high single-digit instrumentation growth. Despite some softness in TA, overall results surpassed expectations, with Batra underscoring sustained momentum from Q1 and Q2, signaling a predictable and robust operational outlook for the life science tools provider.

Analysis

Waters Corporation (NYSE:WAT) management conveyed a message of consistent operational strength and predictability at the Wells Fargo Healthcare Conference. CEO Udit Batra highlighted that the company achieved another quarter of high single-digit growth in its instrumentation business, a key performance driver. While the Thermal Analysis (TA) division was noted as being 'a little soft,' the overall quarterly results surpassed expectations, indicating robust demand in core areas. Batra emphasized that the positive momentum from Q1 continued into Q2, describing the company's execution as reliably consistent. This reinforces a narrative of a stable base business that 'goes from strength to strength,' providing a predictable operational outlook. The discussion also flagged the instrument replacement cycle as a significant topic for the life science tools sector, suggesting it is a key variable for the company's forward-looking performance.

Key Decisions for Investors

• Given the reported high single-digit instrumentation growth and better-than-expected quarterly performance, investors could view the company's consistent execution as a strong positive signal for their investment thesis.
• It is crucial to monitor for further details on the instrument replacement cycle and any persistent softness in the TA division, as these factors represent key potential headwinds or tailwinds to the current growth narrative.
• The CEO's emphasis on a predictable business model suggests a lower operational risk profile, which may warrant a premium for investors prioritizing stability within the life science tools sector.